19 May 1998 Photodynamic therapy of supratentorial gliomas
Author Affiliations +
We are updating the results of PDT treatment in 84 patients with supratentorial gliomas. These patients received 2 mg/kg Photofin iv. 12-36 hours prior to surgical resection oftheir tumor or tumor cyst drainage. There were 64 recurrent patients who had failed previous surgery and radiotherapy. The energy density range was 8 150 J/cm2 and the delivered light energy range was 440 -7200 J (median=1700J). The median survival times in weeks for recurrent glioblastoma (37 patients), malignant astrocytoma (16 patients), malignant mixed astrocytomaoligodentroglioma (7 patients) and ependymoma (4 patients) were 3 1, 50, <64 and <261 weeks, respectively. The thirteen patients with recurrent GBM who received 50J/cm2 had a median survival of 51 weeks. The eight patients with recurrent GBM who received <60 J/cm2 had a median survival of 58weeks. The mortality rate in our total series of 96 PDT treatments for brain tumor (metastatic and non glial primary tumors included) is 3%. The combined serious mortality-morbidity rate is 8%. Patients with malignant astrocytic tumors (GBM and MA) have a very poor prognosis. Nevertheless, PDT is safe in patients with either newly diagnosed or recurrent supratentorial malignant gliomas. There appears to be prolongation of survival in selected patients when an adequate light dose is used. Further improvement in survival may be expected with higher light doses. Key Words: Photodynamic therapy ofbrain tumors, Intracavitary photo-illuminatio
© (1998) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Paul J. Muller, Paul J. Muller, Brian C. Wilson, Brian C. Wilson, "Photodynamic therapy of supratentorial gliomas", Proc. SPIE 3247, Optical Methods for Tumor Treatment and Detections: Mechanisms and Techniques in Photodynamic Therapy VII, (19 May 1998); doi: 10.1117/12.308129; https://doi.org/10.1117/12.308129

Back to Top